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Abstract It has previously been shown that immune
complexes (IC) of a given biomarker with class M
immunoglobulins (IgM) provide better performances
compared to the unbound biomarker in a number of cancer
entities. In the present work, we investigated IC of IgM-Ab
as a potential biomarker for Alzheimer’s disease (AD).
Ab–IgM concentration has been measured in 75 plasma
samples from patients with AD, individuals with mild
cognitive impairment (MCI), and healthy age- and sex-
matched controls (HC). To characterize the fractions
associated with Ab, pooled plasma samples were subjected
to gel-ﬁltration analysis. Size-separated fractions were
analyzed for the presence of Ab using a sandwich ELISA
assay. A strong reactivity was observed in the high
molecular weight IgM ([500 kDa) and 150 kDa (IgG)
fractions indicating that blood Ab is strongly associated
with antibodies. Using an ELISA assay detecting Ab–IgM
complexes, we observed that high levels of Ab–IgMs were
detectable in HC and MCI patients; however, there was no
signiﬁcant difference to the AD group.
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Introduction
The earliest pathological events leading to Alzheimer’s
disease (AD) are estimated to occur 10–20 years before the
appearance of the ﬁrst cognitive changes in affected
patients (Price and Morris 1999; Yamaguchi et al. 2001).
Therefore, identiﬁcation of biomarkers predictive for AD
might allow screening for individuals who may beneﬁt
from preventive therapies before the development of cog-
nitive impairment. The Ab42 peptide is supposed to have a
central role in the pathogenesis of AD (Hardy and Selkoe
2002), and its measurement in the cerebrospinal ﬂuid
(CSF) became nowadays a routine diagnostic procedure
with 75–95% sensitivity and speciﬁcity (Blennow 2004;
Jensen et al. 1999; Lewczuk et al. 2004). Unfortunately,
CSF and blood levels of Ab do not correlate, neither in AD
patients (Mehta et al. 2001) nor in healthy controls (Mehta
and Pirttila 2005). On the other side, it has been also shown
that there is a correlation between CSF and plasma levels
of Ab40 and Ab42 in healthy individuals, whereas no such
correlation could be seen for AD or MCI cases (Giedraitis
et al. 2007).
Studies on plasma Ab levels have shown contradictory
results, ranging from increased Ab40 and decreased Ab42
in AD patients compared to healthy controls (Xu and
Gaskin 2008), no differences (Fukumoto et al. 2003;
Vanderstichele et al. 2000) or increased Ab42 in AD
patients (Matsubara et al. 1999). The different ﬁndings in
these studies may be due to differences in study designs,
including variations in age and disease severity of included
subjects. A longitudinal study showed that plasma Ab40
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DOI 10.1007/s00702-009-0224-yand Ab42 levels measured at age 70 years were not sig-
niﬁcantly associated with incident AD (Sundelof et al.
2008). All of the studies though, have shown substantial
overlap in plasma Ab40 and Ab42 levels between patients
and controls, thus limiting the diagnostic value of plasma
Ab assessment. Although the signiﬁcance of Ab for diag-
nosing Alzheimer’s disease is controversial, high plasma
concentrations of Ab40 and low plasma concentrations of
Ab42 indicate an increased risk of dementia (reviewed in
Kawarabayashi and Shoji 2008). Nonetheless, analysis of
plasma instead of CSF would be highly desirable because
of its better accessibility and less invasive sampling pro-
cedure. Plasma Ab levels are commonly quantiﬁed with
enzyme-linked immunoabsorbent assays (ELISA) using
antibodies against a variety of Ab epitopes (for example
Mehta et al. 2000; Suzuki et al. 1994). Quantiﬁcation of Ab
in blood is technically difﬁcult and limited by the fact that
most of it is bound to blood components, including lipids
serum albumin, a2-macroglobulin, immunoglobulins,
apolipoprotein J, transthyritin, apoferritin, as well as
complement components C1q and C3 (Biere et al. 1996;
Kuo et al. 2000).
Besides the detection of biochemical AD markers,
autoimmune responses to molecules speciﬁc to AD
pathology have become a current research focus (Gruden
et al. 2004; Nath et al. 2003). There seems to be a reduction
in the magnitude of lymphocyte stimulation by APP in AD
patients (Trieb et al. 1996), and naturally occurring anti-Ab
antibodies seem to be present in sera and CSF of AD
patients and healthy controls (Du et al. 2001). However,
whether autoimmunity plays a direct role in the patho-
genesis of AD is still open to debate (McGeer and McGeer
2001; Singh 1997; Tarkowski et al. 2003).
In the present study, the level of circulating immune
complexes (ICs) between Ab and class M immunoglobu-
lins (IgM) has been investigated, because ICs have been
shown to be relevant biomarkers for different types of
cancers (Beneduce et al. 2005, 2006; Castaldi et al. 2005),
showing an improved diagnostic power compared to the
free biomarker protein.
Materials and methods
Patients and samples
Plasma samples (stored at -70C) from 30 out-patients
with mild to moderate AD, 15 patients with mild cognitive
impairment (MCI) and 30 healthy controls (HC) were
analyzed. The patients were recruited at the Memory Clinic
at the Department of Geriatrics, Uppsala University Hos-
pital. All AD patients were diagnosed according to DSM
IV (American Psychiatric Association 2000) and NINCDS-
ADRDA (McKhann et al. 1984). The MCI patients met the
Petersen criteria (Winblad et al. 2004) for MCI.
Gel ﬁltration
Plasma samples from ﬁve AD patients and ﬁve healthy
controls showing high reactivity to Ab–IgM immune
complexes in a preliminary assay were grouped and ana-
lyzed by gel-ﬁltration HPLC. 500 ll of pooled samples
were analyzed using a gel-ﬁltration column Superdex 200
10/300 GL (GE Healthcare, Freiburg, Germany) on an
ACTA Basic system (GE Healthcare, Freiburg, Germany).
The elution was carried out in PBS at a ﬂow rate of 1 ml
per minute, and sample absorbance was monitored at
280 nm. Fractions were collected every 30 s, immunore-
activity was tested by ELISA and the fractions corre-
sponding to the highest immunoreactivity were pooled and
used as reference standard. Before running the samples, a
calibration run was carried out according to the manufac-
turer’s instructions.
ELISA assay to detect Ab
The Ab level in gel-ﬁltration fractions was determined as
follows: 96-well ELISA plates were coated with 50 ll per
well of 1 lg/ml of mouse anti-human Ab antibody directed
against residues 17-24 (4G8, Signet Laboratories, Dedham,
MA, USA) in PBS at 4C overnight and then blocked for
2 h with 3% BSA in PBS at 37C. After blocking, 50 llo f
gel-ﬁltration fractions in PBS containing 1% BSA and
0.05% Tween 20 (PBS-B-T) were incubated for 1.5 h at
37C. The wells were then washed with PBS containing
0.05% Tween 20 and incubated with 50 ll of rabbit
polyclonal anti-Ab 692 (generous gift from Gerd Mult-
haup, Free University of Berlin) at a 1:1,000 dilution in
PBS-B-T for 1.5 h at 37C. Ab was revealed using per-
oxidase-conjugated goat anti-rabbit IgG (Dako, Glostrup,
Denmark) in a 1:1,000 dilution in PBS-B-T and developed
with TMB (Pierce manufacturing, Appleton, IL, USA) and
hydrogen peroxide as substrate. The results of Ab deter-
mination in the gel-ﬁltration fractions were reported in
optical density.
ELISA assay to detect Ab–IgM immune complexes
96-well ELISA plates were coated with 50 lL per well of
1 lg/mL 4G8 antibody (Signet Laboratories, Dedham,
MA, USA) in PBS at 4C overnight and then blocked for
2 h with 3% BSA in PBS. After blocking, 50 ll of serially
diluted reference standard or samples in PBS-B-T were
incubated for 1.5 h at 37C. The Ab–IgM complex was
revealed using peroxidase-conjugated anti-human IgM
(Sigma-Aldrich, Munich, Germany) at a dilution of 1:3,000
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oxide as the substrate. Ab–IgM IC levels in the plasma
were expressed in arbitrary units/ml (AU/ml) by using gel-
ﬁltration-puriﬁed Ab–IgM reference standards to design a
calibration curve, where the undiluted standard was
assigned 1,000 AU/ml; concentration was determined by
interpolation of samples absorbance on the calibration
curve. The linear range of the assay was between 3.9 and
62.5 AU/ml. The samples with values above 62.5 AU/ml
were further diluted and re-measured. The assay was
standardized and its analytical performance evaluated:
inter- and intra-assay coefﬁcient of variation (CV) was less
than 10%. Ab–IgM cut-off was selected as the best com-
bination of speciﬁcity and sensitivity according to the
receiver-operating characteristic (ROC) curve.
Western blot
Gel-ﬁltration fractions corresponding to 280 nm absor-
bance peaks were separated on a 4–12% variogel (Anamed,
Groß-Bieberau, Germany) and then transferred to a nitro-
cellulose membrane. The membrane was heated in PBS in
a microwave for 5 min and then blocked in 10% non-fat
dry milk in TBS containing 0.05% Tween (TBS-T) for 1 h
at room temperature. Blots were then incubated with per-
oxidase-conjugated goat anti-human IgM (Sigma-Aldrich)
at 1:1,000 in TBS-T for 2 h or, alternatively, with a pri-
mary antibody directed against Ab residues 4-10 (W0-2,
The Genetics Company, Switzerland) overnight at 4C and
secondary peroxidase-conjugated antibodies for 2 h at
room temperature. Protein bands were revealed using
chemiluminescence solution and peroxide hydrogen as
substrates on a Curix60 developing machine (Agfa-Gevaert
N.V., Mortsel, Belgium).
Data analysis
All biomarker values were expressed as mean val-
ues ± standard deviation. Differences between the groups
were determined by ANOVA followed by Student t tests.
The diagnostic powers were determined by ROC curve
analysis. Chi-square test on independence was used to
analyze, if the gender distribution was signiﬁcantly dif-
ferent between the three groups and if there is a difference
between the two patient groups in relation to the number of
family members with dementia. All analyses were per-
formed using GraphPad Prism (GraphPad software, Inc.,
La Jolla, CA, USA and SPSS 16 for Windows). Signiﬁ-
cance level was a = 0.05. All tests were two-tailed.
Results
There were no signiﬁcant age differences between the three
groups [Alzheimer patients (AD), MCI and healthy con-
trols] (F = 0.3, df = 2, 72; P = 0.74). Patients with MCI
diagnosis were not signiﬁcantly older at onset of the dis-
ease than AD patients (F = 2.3, df = 1, 42; P = 0.13). As
expected, the mean MMSE score was higher in MCI
compared to AD patients (F = 44.3, df = 1, 40;
P\0.0005). Gender distribution was not signiﬁcantly
different between the three groups (Chi
2 = 1.2, df = 2;
P = 0.55) and the proportion of family members with
dementia did not differ signiﬁcantly between the two
patients groups (Chi
2 = 0.8, df = 1; P = 0.38) (Table 1).
In order to identify circulating Ab–IgM complexes,
plasma samples from ten individuals were pooled and
analyzed by gel ﬁltration. Fractions collected from the
column were tested for the presence of generic Ab and Ab–
IgM complexes using ELISA assays. A strong immunore-
activity against Ab was observed in the fraction eluting at
high molecular weight ([500 kDa) (Fig. 1a). In the same
fraction high reactivity for ICs of Ab with IgM was also
found, thus providing the ﬁrst evidence of the occurrence of
circulating Ab–IgM complexes (Fig. 2c). Reactivity for
generic Ab was also found in the fractions eluting at
150 kDa (IgG fraction) and at low molecular weight (not
shown). Reactivity against the monomeric form of Ab has
been found in all fractions, conﬁrming previous observa-
tions (Kuo et al. 2000). The fractions contained components
Table 1 Demographic data of the studied groups
AD MCI HC Chi
2 df P
Gender (male, female) M: 12, F: 18 M: 8, F: 7 M:11, F: 19 1.2 2 0.55
Dementia in family Yes: 16, no: 12 Yes: 6, no: 8 0.8 1 0.38
n m ± SD n m ± SD n m ± SD Fd fP
Age (years) 30 72.3 ± 6.7 15 73.7 ± 4.3 30 72.5 ± 5.2 0.3 2, 72 0.74
Age at onset (years) 30 67.9 ± 7.9 14 71.4 ± 4.9 2.3 1, 42 0.13
MMSE (at screening) 27 17.3 ± 6.1 15 27.9 ± 1.3 44.3 1, 40 \0.0005
AD Alzheimer’s disease, MCI mild cognitive impaired individuals, HC healthy controls, m mean, SD standard deviation, Chi
2 Chi-square
statistic, F F-statistic, df degrees of freedom, P probability, M male, F female
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123migrating at the expected molecular weight for reduced IgM
that were stained by antihuman IgM antibodies (Fig. 1b).
To assess the relevance of these ﬁndings, plasma sam-
ples from 75 patients with AD, MCI, and from healthy
donors were analyzed for the presence of Ab–IgM ICs.
Serial dilutions of the gel ﬁltration-puriﬁed IC fraction
have been used to draw a reference calibration curve.
By interpolation with the standard curve, Ab–IgM IC
concentration in the plasma samples has been expressed in
arbitrary units (AU)/ml. According to ANOVA test, no
signiﬁcant differences among the three diagnostic groups
were observed (Student t test P value AD vs. HC = 0.18,
AD vs. MCI = 0.61, MCI vs. HC = 0.10) (Fig. 3).
ROC curve analysis showed that speciﬁcity was only
46.67% when sensitivity was set at 80%, and by setting
speciﬁcity above 80%, sensitivity was 26.67% (Table 2).
Discussion
The aim of the present study was to analyze the serological
proﬁle of samples from AD and MCI patients, and healthy
controls, regarding the levels of Ab–IgM complexes, and to
evaluate a possible correlation between the immunological
proﬁles of individuals with AD. Immune complexes, in
fact, have recently been proven to correlate better than
unbound biomarkers with pathology in different cancer
entities (Beneduce et al. 2005, 2007, 2008; Castaldi et al.
2005), which are characterized by an over- or mis-pro-
duction of an endogenous protein. At present, only CSF
Ab42 levels is a well established Ab-related AD biomarker
with high sensitivity and speciﬁcity (Andreasen et al. 2001;
Galasko et al. 1998; Kanai et al. 1998; Lewczuk et al.
2004; Tapiola et al. 2000). Unfortunately, there seems to be
no correlation between CSF and blood Ab level, as shown
by several groups (Matsumoto et al. 2007; Mehta et al.
2000, 2001; Vanderstichele et al. 2000). A longitudinal
study showed that CSF Ab42 decreases within 12 months
signiﬁcantly in AD patients, while Tau and Phospho-Tau
did not (Kessler et al. 2008). Although much better for
clinical practice, blood-based Ab levels are controversially
discussed as a useful biomarker for AD. Studies have
shown a decreased level of Ab in AD subjects (Pesaresi
et al. 2006; Xu and Gaskin 2008), while others showed an
Fig. 1 a Gel-ﬁltration HPLC of
pooled plasma samples. Proteins
are separated according to their
molecular weight, with the
larger proteins eluting ﬁrst.
Total protein concentration of
each fraction was measured at
280 nm (gray line). The
characteristic peaks were as
follows: empty volume with a
MW[500 kDa (IgMs), IgGs
with a MW of *150 kDa, and
the albumin peak at *66 kDa.
A direct ELISA performed on
each fraction to measure the
quantity of generic Ab
(diamonds) shows that most of
Ab elutes in the empty volume
and IgG fractions suggesting
that Ab in the blood is strongly
associated with antibodies.
b Western blot against Ab in the
empty volume (IgM) fraction
and IgM showing the presence
of Ab in the IgM fraction
916 A. Marcello et al.
123increase of Ab concentration in the plasma of AD patients
(Kosaka et al. 1997; Matsubara et al. 1999), or no statistical
differences (Fukumoto et al. 2003; Tamaoka et al. 1996).
The same inconsistency emerged from a series of pro-
spective studies, in which a higher risk for developing AD
has been associated both with higher baseline plasma Ab42
concentration (Pomara et al. 2005) or higher Ab40 with no
effect on Ab42 (van Oijen et al. 2006). Finally, Graff-
Radford et al. (2007) linked a high risk for developing AD
to a lower Ab42/40 ratio. Plasma anti-Ab autoantibody
concentration has also been investigated by several groups.
Titers of anti-Ab42 autoantibodies were reported to be
lower in AD patients compared to healthy individuals (Du
et al. 2001; Weksler et al. 2002), or higher in AD patients
(Nath et al. 2003). One study reported no correlation
between autoantibodies titers and plasma Ab40 or 42 levels
(Hyman et al. 2001).
The initial goal of this study was to characterize the
occurrence of ICs of Ab in the plasma of AD and MCI
patients and HC, as seen with many cancer biomarkers. It is
well known that IgM complexes are in equilibrium in blood
with the unbound respective antigen and are used as reli-
able blood biomarkers for diagnosis of different cancer
entities. It would make sense that the same equilibrium
holds true for any IgM complex in blood. Already estab-
lished immune complexes as biomarkers include: PSA–
IgM for prostate cancer (Beneduce et al. 2007), carcino-
embryonic antigen–IgM for colorectal cancer (Castaldi
et al. 2005) alpha fetoprotein–IgM and squamous cell
carcinoma antigen-IgM for liver cancer (Beneduce et al.
2004, 2005). Moreover, IgM immune complexes have also
been shown to be uncorrelated with basal IgM levels
(Beneduce 2008). Nydegger (2007) discussed in a review
article biochemical properties of immune complexes in
general, their formation and their equilibrium state, stating
that immune complex interaction is extremely high com-
pared to other biochemical interactions.
Plasma samples from 30 AD patients, 15 MCI patients,
and 30 age- and sex-matched HC have been analyzed to
determine the levels of circulating Ab–IgM ICs. After gel-
ﬁltration and size fractionation, Ab was primarily found to
be associated with the IgM and the IgG fractions using an
ELISA. This is the ﬁrst characterization of circulating Ab–
IgM complexes in AD. The Ab–IgM assay did not show
any signiﬁcant difference among the three groups, in
contrast with previous ﬁndings (Gruden et al. 2007),
Fig. 2 a Sandwich ELISA. 96-well titer plates are coated with anti-
Ab (4G8). After incubation with plasma samples, the wells are
washed and incubated with an anti-IgM heavy chain antibody
conjugated with HRP. Signal of bound molecules is therefore only
produced by complexes of both IgM and antigen. b Calibration curve
obtained by serial dilutions of the IgM fraction. c Ab-IgM (diamonds)
immune complexes in the fractions derived from gel-ﬁltration HPLC
compared to total protein concentration (solid line)
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immunity in AD, IC levels cannot be used as a diagnostic
marker. It should be noted, however, that variability of IC
level was high within the groups. This high variance
leading to an overlap between AD patients and healthy
controls might be partly due to biological variability.
Consensus criteria for a suitable biomarker (Trojanowski
et al. 1998) for AD were however not met.
On the other hand, the presence of circulating ICs
against neuronal antigens supports the notion that autoim-
mune-mediated processes may be involved in neurode-
generative disorders. Further investigations are needed to
elucidate the pathophysiological role of these complexes
and the signiﬁcance of autoantibodies in AD in general.
Whether their role is neuroprotective or neurotoxic is still
unknown. They may be seen both as a possible protective
factor for AD, or as a risk factor in case of an unbalanced
level. In any case, autoimmunity-driven homeostasis is a
natural process and its understanding may be useful in both
diagnosing and treating AD; there are evidences for a
therapeutic use of anti-Ab antibodies as it is being shown
by current experimental immunotherapeutic approaches.
Hock et al. (2003) showed that active immunization against
aggregated Ab42 led to a slower cognitive decline in a
dose-dependent fashion; patients generating a higher titer
of anti-Ab antibodies performed better in cognitive test
than patients who did not respond to the immunization
protocol. The increase in antibody titer did not correspond
to a decrease in Ab blood levels. In contrast, signiﬁcant
changes were observed in serum and CSF of patients with
AD after treatment with intravenous Ab IgGs (Dodel et al.
2002).
The levels of Ab autoantibodies of the IgG class for
monitoring the effect of passive or active immunization in
AD have already been evaluated by recent studies. It is
speculative to discuss a possible role of Ab–IgM levels as a
predictive indicator of immunotherapy efﬁcacy. A possible
hypothesis includes that they serve as a ‘‘buffering system’’
to keep free potential toxic endogenous peptides and pro-
teins under homeostatic control and lead to their clearance
(Gruden et al. 2007). Previous studies have shown the
presence of anti-Ab autoantibodies (Xu and Gaskin 1997)
and circulating IC of Ab and IgGs of different classes
(Gruden et al. 2004). APP transgenic mice injected intra-
venously with monoclonal anti-Ab antibody showed a
rapid and massive increase of CNS-derived Ab in the
plasma suggesting that antibodies may participate in Ab
clearance from the brain (DeMattos et al. 2001). However,
whether this immune activity is defensive or toxic is still a
matter of debate (Geylis et al. 2005; Nath et al. 2003;
Woulfe et al. 2002). It will be interesting to evaluate in
future studies possible relationships of Ab-IC levels with
the clinical development of MCI patients, and with AD
patients’ response to immune therapies.
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